

**Letter to the editor:**

**QUANTIFICATION OF THREE-DIMENSIONAL STRUCTURES  
IN LIVER TISSUE: BILE CANALICULAR  
AND SINUSOIDAL NETWORKS**

Hassan Ahmed<sup>1,\*</sup>, Mosaab A. Omar<sup>2</sup>, Ahmed M. Abdou<sup>3</sup>

Faculty of Veterinary Medicine, South Valley University, 83523 Qena, Egypt

<sup>1</sup> Department of Physiology

<sup>2</sup> Department of Parasitology

<sup>3</sup> Department of Forensic Medicine and Veterinary Toxicology

\* Corresponding author: Dr. Hassan Ahmed, Department of Physiology, Faculty of Veterinary Medicine, South Valley University, 83523 Qena, Egypt

E-mail: [hassan-younes@vet.svu.edu.eg](mailto:hassan-younes@vet.svu.edu.eg)

Dear Editor,

Unpredicted hepatotoxicity represents the most frequent reason for withdrawal of drugs from the market (Godoy et al., 2013). Therefore, large efforts are currently undertaken to establish improved techniques to predict hepatotoxicity (Shimizu et al., 2009; O'Brien et al., 2006; Okwa et al., 2013; Oloyede et al., 2013; Lu et al., 2013; Godoy et al., 2009). The perhaps most intensive activities in this field of research can be observed in establishment of hepatocyte *in vitro* systems (Godoy et al., 2013; Hewitt et al., 2007; Ilkavets et al., 2013; Hengstler et al., 2012, 2014; Hammad et al., 2013; Hammad, 2013). One of the concepts of this type of *in vitro* research is that stress responses to chemicals are similar *in vitro* and *in vivo*. Therefore, activation of stress response pathways *in vitro* may indicate a potential hazard (Jennings, 2013; Vinken et al., 2014). Although hepatocyte *in vitro* systems have promoted our understanding of mechanisms (Meyer et al., 2011; Schug et al., 2013; Godoy et al., 2010, 2012; Zellmer et al., 2010; Hengstler et al., 2014) it has also become clear that a full replacement of animal experiments for toxicity testing will not be possible within the next one or two decades (Adler et al., 2011; Hammad, 2013). Reasons are difficulties to include xenobiotic metabolism into *in vitro* tests, to model interactions between cell types, to extrapolate from *in vivo* doses to *in vitro* concentrations and to simulate the consequences of long term exposure *in vitro* (Tice et al., 2013; Ghallab, 2013). However, one additional aspect may currently be underestimated: we still know too little about mechanisms of *in vivo* toxicity to establish *in vitro* systems in a way that the most critical *in vivo* processes are recapitulated. Although this may seem paradoxical, progress in replacement of animal experiments currently depends on progress in understanding the mechanisms of toxicity *in vivo*.

Histological alterations often constitute a fingerprint of toxic mechanisms (Hammad et al., 2014). Particularly, liver toxicity often leads to altered tissue microarchitecture (Höhme et al., 2007; Hoehme et al., 2010; Braeuning et al., 2010; Schreiber et al., 2011). Moreover, current studies on liver histology largely rely on image analysis of two-dimensional pictures. However, many aspects of liver tissue architecture such as the complex bile canalicular and sinusoidal networks can be much better quantified using three-dimensional reconstructions. In this context, it represents an important step forward that Dr. Hammad and his team have

established a technique for staining, three-dimensional reconstruction and quantification of liver microarchitecture (Hammad et al., 2014). These protocols which can be applied under routine conditions allow: (1) the simultaneous staining of bile canalicular and sinusoidal networks in approximately 100  $\mu\text{m}$  thick liver tissue blocks; (2) identification of S-phase positive cells whereby the position, size and shape of all individual cells is robustly captured; (3) quantification of key parameters such as hepatocyte volume, the fraction of hepatocytes in contact with neighboring hepatocytes, sinusoids and bile canaliculi. Parameters of the bile canalicular network include the length and branching angles of individual canaliculi, the number of dead end branches and the length of canaliculi per tissue volume. Further, parameters that can be quantified are the radius of the sinusoids, percentage of vessel volume in relation to tissue volume, the branching angle and the length of intersection branches of sinusoids.

Briefly, key parameters of liver tissue microarchitecture can now be quantified routinely. It can be expected that the novel technique will lead to a more precise and robust characterization of hepatotoxicity.

## REFERENCES

- Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. *Arch Toxicol* 2011;85:367-485.
- Braeuning A, Singh Y, Rignall B, Buchmann A, Hammad S, Othman A et al. Phenotype and growth behavior of residual  $\beta$ -catenin-positive hepatocytes in livers of  $\beta$ -catenin-deficient mice. *Histochem Cell Biol* 2010;134:469-81.
- Ghallab A. *In vitro* test systems and their limitations *EXCLI J* 2013;12:1024-6.
- Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A et al. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. *Hepatology* 2009;49:2031-43.
- Godoy P, Lakkapamu S, Schug M, Bauer A, Stewart JD, Bedawi E et al. Dexamethasone-dependent versus independent markers of epithelial to mesenchymal transition in primary hepatocytes. *Biol Chem* 2010;391:73-83.
- Godoy P, Reif R, Bolt HM. Alcohol hepatotoxicity: Kupffer cells surface to the top. *Arch Toxicol* 2012;86:1331-2.
- Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S et al. Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Arch Toxicol* 2013;87:1315-530.
- Hammad S. Advances in 2D and 3D *in vitro* systems for hepatotoxicity testing. *EXCLI J* 2013;12:993-6.
- Hammad S, Marchan R, Hengstler JG. Cutting-edge topics in research on animal sciences. *J Exp Appl Anim Sci* 2013;1:1-3.
- Hammad S, Hoehme S, Friebel A, von Recklinghausen I, Othman A, Begher-Tibbe B et al. Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis. *Arch Toxicol* 2014;88:1161-83.
- Hengstler JG, Marchan R, Leist M. Highlight report: towards the replacement of *in vivo* repeated dose systemic toxicity testing. *Arch Toxicol* 2012;86:13-5.
- Hengstler JG, Hammad S, Ghallab A, Reif R, Godoy P. *In vitro* systems for hepatotoxicity testing. In: Bal-Price A, Jennings P (eds.): *In vitro* toxicology systems. *Methods in pharmacology and toxicology* (pp 27-44). New York: Springer Science+Business Media, 2014.
- Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. *Drug Metab Rev* 2007;39:159-234.

- Höhme S, Hengstler JG, Brulport M, Schäfer M, Bauer A, Gebhardt R et al. Mathematical modelling of liver regeneration after intoxication with CCl<sub>4</sub>. *Chem Biol Interact* 2007;168:74-93.
- Hoehme S, Brulport M, Bauer A, Bedawy E, Schorrmann W, Hermes M et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. *Proc Natl Acad Sci U S A* 2010;107:10371-6.
- Ilkavets I. A special issue about hepatotoxicity and hepatocyte *in vitro* systems. *Arch Toxicol* 2013;87:1313-4.
- Jennings P. Stress response pathways, toxicity pathways and adverse outcome pathways. *Arch Toxicol* 2013;87:13-4.
- Lu Y, Pei Y, Shao Y, Yan S, Ma L, Fang F et al. Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis. *EXCLI J* 2013;12:115-7.
- Meyer C, Godoy P, Bachmann A, Liu Y, Barzan D, Ilkavets I et al. Distinct role of endocytosis for Smad and non-Smad TGF- $\beta$  signaling regulation in hepatocytes. *J Hepatol* 2011;55:369-78.
- O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR et al. High concordance of drug-induced human hepatotoxicity with *in vitro* cytotoxicity measured in a novel cell-based model using high content screening. *Arch Toxicol* 2006;80:580-604.
- Okwa IB, Akindele AJ, Agbaje EO, Oshinuga OT, Anunobi CC, Ademeyi OO. Effect of subclinical, clinical and supraclinical doses of calcium channel blockers on models of drug-induced hepatotoxicity in rats. *EXCLI J* 2013;12:231-50.
- Oloyede GK, Adaramoye OA, Oguntokun OJ. Phytochemical and hepatotoxicity studies on *Adansonia digitata* leaf extracts. *J Exp Appl Anim Sci* 2013;1:25-34.
- Schreiber S, Rignall B, Braeuning A, Marx-Stoelting P, Ott T, Buchmann A et al. Phenotype of single hepatocytes expressing an activated version of  $\beta$ -catenin in liver of transgenic mice. *J Mol Histol* 2011;42:393-400.
- Schug M, Stöber R, Heise T, Mielke H, Gundert-Remy U, Godoy P et al. Pharmacokinetics explain *in vivo/in vitro* discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. *Arch Toxicol* 2013;87:337-45.
- Shimizu S, Atsumi R, Itokawa K, Iwasaki M, Aoki T, Ono C et al. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. *Arch Toxicol* 2009;83:701-7.
- Tice RR, Austin CP, Kavlock RJ, Bucher JR. Improving the human hazard characterization of chemicals: a Tox21 update. *Environ Health Perspect* 2013;121:756-65.
- Vinken M, Whelan M, Rogiers V. Adverse outcome pathways: hype or hope? *Arch Toxicol* 2014;88:1-2.
- Zellmer S, Schmidt-Heck W, Godoy P, Weng H, Meyer C, Lehmann T et al. Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. *Hepatology* 2010;52:2127-36.